Novartis set to purchase Tourmaline Bio in a $1.4 billion agreement
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 09 2025
0mins
Source: Yahoo Finance
Acquisition Announcement: Novartis will acquire Tourmaline Bio for $48 per share, valuing the company at $1.4 billion on a fully diluted basis.
Future Plans: The deal is expected to close in the fourth quarter, with Tourmaline becoming an indirect, wholly owned subsidiary of Novartis.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
